Literature DB >> 6734692

Relationship between the cardiovascular effects and steady-state kinetics of clonidine in hypertension. Demonstration of a therapeutic window in man.

M Frisk-Holmberg, L Paalzow, L Wibell.   

Abstract

Clonidine was given orally as monotherapy in increasing daily doses from 3.1 to 25.7 micrograms/kg to patients with essential hypertension (n = 6). When a steady state concentration in plasma was reached at each dose level, the blood pressure (BP) and heart rate were measured during a dosage interval. Effect time-plasma concentration data were submitted to nonlinear regression analysis, which showed that the observed BP effects could be dissociated into depressor and pressor components. A window for the anti-hypertensive effect was established. At a plasma clonidine concentration of 0.65 +/- 0.07 ng/ml 50% of the maximal depressor effect was found, and it was only separated by a factor of 2 from the half maximal pure pressor concentration in plasma. No relationship between the change in heart rate and the plasma clonidine was observed. The findings strengthen the importance of close monitoring of clonidine therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734692     DOI: 10.1007/BF00548760

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

2.  Steady state plasma concentration of clonidine and its relation to the effects on blood pressure in normotensive and hypertensive rats.

Authors:  S Christersson; M Frisk-Holmberg; L Paalzow
Journal:  J Pharm Pharmacol       Date:  1979-06       Impact factor: 3.765

3.  Multiple receptor responses: a new concept to describe the relationship between pharmacological effects and pharmacokinetics of a drug: studies on clonidine in the rat and cat.

Authors:  L K Paalzow; P O Edlund
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

4.  Determination of clonidine in human plasma by glass capillary gas chromatography with electron-capture detection.

Authors:  P O Edlund
Journal:  J Chromatogr       Date:  1980-01-04

5.  The effectiveness of clonidine as an antihypertensive in a two-dose regimen.

Authors:  M Frisk-Holmberg
Journal:  Acta Med Scand       Date:  1980

6.  The antihypertensive mechanism of clonidine in man. Evidence against a generalized reduction of sympathetic activity.

Authors:  B G Wallin; M Frisk-Holmberg
Journal:  Hypertension       Date:  1981 May-Jun       Impact factor: 10.190

7.  Apparent resistance to hypotensive effect of clonidine.

Authors:  L M Wing; J L Reid; D S Davies; H J Dargie; C T Dollery
Journal:  Br Med J       Date:  1977-01-15

8.  Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy.

Authors:  M Frisk-Holmberg; L Paalzow; P O Edlund
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

9.  Pharmacokinetics of clonidine in the rat and cat.

Authors:  L K Paalzow; P O Edlund
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

10.  Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients.

Authors:  M Frisk-Holmberg; P O Edlund; L Paalzow
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

View more
  8 in total

Review 1.  Pharmacokinetic considerations in the use of newer transdermal formulations.

Authors:  G Ridout; G C Santus; R H Guy
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

2.  Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension.

Authors:  V Mitrovic; W Patyna; J Hüting; M Schlepper
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

3.  Implication of enterohepatic re-circulation on single dose bioequivalence evaluation of two brands of clonidine hydrochloride tablets in healthy human volunteers.

Authors:  H R Mehta; I K Patel; N H Patel; D M Patel; A B Parmar
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

4.  Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose.

Authors:  L E Domino; S E Domino; M S Stockstill
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

Review 5.  Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  M S Langley; R C Heel
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

7.  Clinical Practice: Should we Radically Alter our Sedation of Critical Care Patients, Especially Given the COVID-19 Pandemics?

Authors:  D Longrois; F Petitjeans; O Simonet; M de Kock; M Belliveau; C Pichot; Th Lieutaud; M Ghignone; L Quintin
Journal:  Rom J Anaesth Intensive Care       Date:  2021-01-04

8.  How should dexmedetomidine and clonidine be prescribed in the critical care setting?

Authors:  Dan Longrois; Fabrice Petitjeans; Olivier Simonet; Marc de Kock; Marc Belliveau; Cyrille Pichot; Thomas Lieutaud; Marco Ghignone; Luc Quintin
Journal:  Rev Bras Ter Intensiva       Date:  2022-01-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.